882033-96-7Relevant articles and documents
QUINAZOLINONES AS PARP14 INHIBITORS
-
Paragraph 1035; 1037, (2019/07/10)
The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS
-
, (2016/07/05)
Disclosed are chemical entities of Formula (I): wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists
Di Fabio, Romano,Giovannini, Riccardo,Bertani, Barbara,Borriello, Manuela,Bozzoli, Andrea,Donati, Daniele,Falchi, Alessandro,Ghirlanda, Damiano,Leslie, Colin P.,Pecunioso, Angelo,Rumboldt, Giovanna,Spada, Simone
, p. 1749 - 1752 (2007/10/03)
The SAR of a new series of tetrahydrocarbazole derivatives is described: the appropriate decoration of this template led to the identification of a new class of NPY-1 antagonists showing good in vitro potency and a promising in vivo pharmacokinetic profil
